Loading clinical trials...
Loading clinical trials...
Phase 1/2a, Double-blind, Placebo-controlled, Single and Multiple Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ARO-DIMERPA in Adult Subjects With Mixed Hyperlipidemia
Conditions
Interventions
ARO-DIMERPA
Placebo
Locations
1
New Zealand
Research Site 1
Christchurch, New Zealand
Start Date
December 22, 2025
Primary Completion Date
June 1, 2026
Completion Date
July 1, 2027
Last Updated
January 9, 2026
Lead Sponsor
Arrowhead Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions